Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from VicPlas International Ltd. ( (SG:569) ) is now available.
VicPlas International Ltd has addressed shareholder inquiries regarding its medical devices segment, Forefront, ahead of its upcoming AGM. The company highlights the ‘stickiness’ of its revenue streams, as customers rarely switch suppliers due to extensive testing and revalidation processes. Forefront’s products, primarily single-use medical devices, benefit from long-term customer contracts, typically spanning 8-10 years. The company also outlines its strategy for capital expenditure to expand production capacity and develop capabilities, ensuring machinery versatility across different projects. Pricing is contractually fixed with periodic reviews to accommodate variables like foreign exchange and raw material cost fluctuations.
The most recent analyst rating on (SG:569) stock is a Hold with a S$0.10 price target. To see the full list of analyst forecasts on VicPlas International Ltd. stock, see the SG:569 Stock Forecast page.
More about VicPlas International Ltd.
VicPlas International Ltd, incorporated in Singapore, operates in the medical devices industry through its subsidiary Forefront. The company focuses on manufacturing medical devices, with a strong emphasis on product integration and long-term customer relationships.
Average Trading Volume: 178,232
Technical Sentiment Signal: Hold
Current Market Cap: S$48.04M
For detailed information about 569 stock, go to TipRanks’ Stock Analysis page.